Chen Xiaona, He Yanhong, Fu Wenjun, Sahebkar Amirhossein, Tan Yuhui, Xu Suowen, Li Hong
Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Cell Dev Biol. 2020 Nov 12;8:581015. doi: 10.3389/fcell.2020.581015. eCollection 2020.
Atherosclerosis (AS), the most common underlying pathology for coronary artery disease, is a chronic inflammatory, proliferative disease in large- and medium-sized arteries. The vascular endothelium is important for maintaining vascular health. Endothelial dysfunction is a critical early event leading to AS, which is a major risk factor for stroke and myocardial infarction. Accumulating evidence has suggested the critical roles of histone deacetylases (HDACs) in regulating vascular cell homeostasis and AS. The purpose of this review is to present an updated view on the roles of HDACs (Class I, Class II, Class IV) and HDAC inhibitors in vascular dysfunction and AS. We also elaborate on the novel therapeutic targets and agents in atherosclerotic cardiovascular diseases.
动脉粥样硬化(AS)是冠状动脉疾病最常见的潜在病理状况,是一种发生在大中型动脉的慢性炎症性增殖性疾病。血管内皮对于维持血管健康至关重要。内皮功能障碍是导致AS的关键早期事件,而AS是中风和心肌梗死的主要危险因素。越来越多的证据表明组蛋白脱乙酰酶(HDACs)在调节血管细胞稳态和AS中起关键作用。本综述的目的是就HDACs(I类、II类、IV类)和HDAC抑制剂在血管功能障碍和AS中的作用呈现最新观点。我们还阐述了动脉粥样硬化性心血管疾病中的新型治疗靶点和药物。